Breakthrough CardiAMP Cell Therapy System Discovered for Heart Failure
BioCardia®, Inc revolutionizes heart failure treatment with the groundbreaking CardiAMP® Cell Therapy System.
By harnessing the patient's own bone marrow cells and delivering them to the heart through a minimally invasive, catheter-based procedure, CardiAMP Cell Therapy offers a unique approach. Its pre-procedural screening assay identifies the ideal candidates for cardiac cell therapy, enhancing patient selection.
Designed to enhance the body's natural healing response, CardiAMP Cell Therapy triggers a beneficial paracrine reaction to facilitate heart repair.
Unlike other therapies, CardiAMP Cell Therapy transforms stem cells into new heart cells, reducing patient risks associated with rhythm abnormalities and cell rejection. This innovative treatment significantly improves the lives of heart failure patients.
Not only does this therapy introduce new treatment options for those in need, but it also expedites the procedure compared to traditional methods.
Currently undergoing the CardiAMP Cell Therapy Heart Failure Trial, the system is evaluated for its potential to lower adverse cardiac events, increase survival rates, and enhance patients' quality of life. This breakthrough therapy holds the promise of providing more effective treatment for heart failure.
Recognizing its significance, the U.S. Food and Drug Administration (FDA) has granted the CardiAMP Cell Therapy System the prestigious Breakthrough Device Designation for Heart Failure.
